NASDAQ:BMRA - Biomerica Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.52 -0.13 (-4.91 %) (As of 03/24/2019 04:00 PM ET)Previous Close$2.5173Today's Range$2.50 - $2.6552-Week Range$1.60 - $4.35Volume4,931 shsAverage Volume6,894 shsMarket Capitalization$23.46 millionP/E Ratio-14.81Dividend YieldN/ABeta1.37 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It primarily offers its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the point-of-care and in-hospital/clinical laboratories worldwide. The company is also developing InFoods, an irritable bowel syndrome (IBS) therapy technology and diagnostic-guided therapy, which is in clinical studies to identify specific foods that when removed from the patient's diet can alleviate the patient's IBS symptoms. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California. Receive BMRA News and Ratings via Email Sign-up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Dental equipment & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BMRA Previous Symbol CUSIPN/A CIK73290 Webwww.biomerica.com Phone949-645-2111Debt Debt-to-Equity RatioN/A Current Ratio4.63 Quick Ratio2.54Price-To-Earnings Trailing P/E Ratio-14.81 Forward P/E Ratio-11.44 P/E GrowthN/A Sales & Book Value Annual Sales$5.56 million Price / Sales4.22 Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book5.03Profitability EPS (Most Recent Fiscal Year)($0.17) Net Income$-1,460,000.00 Net Margins-36.36% Return on Equity-45.72% Return on Assets-37.89%Miscellaneous Employees54 Outstanding Shares9,320,000Market Cap$23.46 million Next Earnings Date4/15/2019 (Estimated) OptionableNot Optionable Biomerica (NASDAQ:BMRA) Frequently Asked Questions What is Biomerica's stock symbol? Biomerica trades on the NASDAQ under the ticker symbol "BMRA." How were Biomerica's earnings last quarter? Biomerica, Inc. (NASDAQ:BMRA) announced its quarterly earnings data on Tuesday, January, 15th. The company reported ($0.05) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.06) by $0.01. The business had revenue of $1.50 million for the quarter, compared to the consensus estimate of $1.51 million. Biomerica had a negative return on equity of 45.72% and a negative net margin of 36.36%. View Biomerica's Earnings History. When is Biomerica's next earnings date? Biomerica is scheduled to release their next quarterly earnings announcement on Monday, April 15th 2019. View Earnings Estimates for Biomerica. What price target have analysts set for BMRA? 1 Wall Street analysts have issued 1 year price targets for Biomerica's shares. Their forecasts range from $6.25 to $6.25. On average, they expect Biomerica's stock price to reach $6.25 in the next year. This suggests a possible upside of 148.3% from the stock's current price. View Analyst Price Targets for Biomerica. What is the consensus analysts' recommendation for Biomerica? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biomerica in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biomerica. Has Biomerica been receiving favorable news coverage? Media stories about BMRA stock have been trending neutral recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Biomerica earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an effect on the company's share price in the near term. Who are some of Biomerica's key competitors? Some companies that are related to Biomerica include Straumann (SAUHF), DENTSPLY SIRONA (XRAY), BIOLASE (BIOL), Remedent (REMI), Nobel Biocare (NBHGF) and Sartorius (SARTF). What other stocks do shareholders of Biomerica own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biomerica investors own include Accenture (ACN), Akers Biosciences (AKER), Synergy Pharmaceuticals (SGYP), Champions Oncology (CSBR), Bellerophon Therapeutics (BLPH), Avid Technology (AVID), Marathon Patent Group (MARA), Zynerba Pharmaceuticals (ZYNE), STRATA Skin Sciences (SSKN) and CBRE Group (CBRE). Who are Biomerica's key executives? Biomerica's management team includes the folowing people: Mr. Zackary S. Irani, Chairman & CEO (Age 53)Mr. Francis E. Capitanio, Pres (Age 75)Ms. Janet Moore, CFO, Treasurer, Sec. & Director (Age 68) Who are Biomerica's major shareholders? Biomerica's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Perritt Capital Management Inc. (0.43%). Company insiders that own Biomerica stock include Francis Cano and Zackary S Irani. View Institutional Ownership Trends for Biomerica. Which institutional investors are buying Biomerica stock? BMRA stock was acquired by a variety of institutional investors in the last quarter, including Perritt Capital Management Inc.. Company insiders that have bought Biomerica stock in the last two years include Francis Cano and Zackary S Irani. View Insider Buying and Selling for Biomerica. How do I buy shares of Biomerica? Shares of BMRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Biomerica's stock price today? One share of BMRA stock can currently be purchased for approximately $2.5173. How big of a company is Biomerica? Biomerica has a market capitalization of $23.46 million and generates $5.56 million in revenue each year. The company earns $-1,460,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis. Biomerica employs 54 workers across the globe. What is Biomerica's official website? The official website for Biomerica is http://www.biomerica.com. How can I contact Biomerica? Biomerica's mailing address is 17571 Von Karman Avenue, Irvine CA, 92614. The company can be reached via phone at 949-645-2111. MarketBeat Community Rating for Biomerica (NASDAQ BMRA)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 92 (Vote Outperform)Underperform Votes: 90 (Vote Underperform)Total Votes: 182MarketBeat's community ratings are surveys of what our community members think about Biomerica and other stocks. Vote "Outperform" if you believe BMRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMRA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/24/2019 by MarketBeat.com StaffFeatured Article: What are the benefits of momentum investing?